Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation

Stefano Benedini, Federica Ermetici, Silvia Briganti, Roberto Codella, Ileana Terruzzi, Paola Maffi, Rossana Caldara, Antonio Secchi, Rita Nano, Lorenzo Piemonti, Rodolfo Alejandro, Camillo Ricordi, Livio Luzi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues. Aims: This study aimed at evaluating the effectiveness of rapamycin pre-treatment before pancreatic islet allotransplantation (ITx) in patients with type 1 diabetes mellitus (T1DM). Methods: Forty-one T1DM patients were studied. Thirteen patients with poor glycemic control underwent a short-term rapamycin treatment before ITx (Group 1), and they were compared to 28 patients undergoing ITx without rapamycin pre-treatment (Group 2). Outcomes were daily insulin requirement (DIR), fasting blood glucose, HbA1c, C-peptide and the SUITO index of beta-cell function. A subgroup of patients pre-treated with rapamycin before ITx underwent euglycemic hyperinsulinemic clamp with [6,6-2H2] glucose before and after ITx to evaluate insulin sensitivity. Results: We found a significant reduction in DIR after rapamycin pre-treatment (− 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx. DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (− 37 ± 15 vs. − 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006). Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: − 2.1 ± 1.4%, p = 0.002), while fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups. Hepatic glucose production decreased after rapamycin pre-treatment (− 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (− 1.6 ± 0.6 mg/kg/min, p = 0.015), while no changes in peripheral glucose disposal were observed. Conclusions: Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity. This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance. Clinical Trial: Clinicaltrials.gov NCT01060605; NCT00014911.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalActa Diabetologica
DOIs
StateAccepted/In press - Apr 13 2018

Fingerprint

Islets of Langerhans Transplantation
Sirolimus
Insulin
Insulin Resistance
Glucose
Type 1 Diabetes Mellitus
Fasting
C-Peptide
Therapeutics
Glucose Clamp Technique
Liver
Immunosuppressive Agents
Islets of Langerhans
Blood Glucose
pre-rapamycin
Clinical Trials
Pharmaceutical Preparations

Keywords

  • C-peptide
  • Euglycemic hyperinsulinemic clamp
  • Insulin sensitivity
  • mTOR
  • Pancreatic islet allotransplantation

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Benedini, S., Ermetici, F., Briganti, S., Codella, R., Terruzzi, I., Maffi, P., ... Luzi, L. (Accepted/In press). Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation. Acta Diabetologica, 1-8. https://doi.org/10.1007/s00592-018-1141-z

Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation. / Benedini, Stefano; Ermetici, Federica; Briganti, Silvia; Codella, Roberto; Terruzzi, Ileana; Maffi, Paola; Caldara, Rossana; Secchi, Antonio; Nano, Rita; Piemonti, Lorenzo; Alejandro, Rodolfo; Ricordi, Camillo; Luzi, Livio.

In: Acta Diabetologica, 13.04.2018, p. 1-8.

Research output: Contribution to journalArticle

Benedini, S, Ermetici, F, Briganti, S, Codella, R, Terruzzi, I, Maffi, P, Caldara, R, Secchi, A, Nano, R, Piemonti, L, Alejandro, R, Ricordi, C & Luzi, L 2018, 'Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation', Acta Diabetologica, pp. 1-8. https://doi.org/10.1007/s00592-018-1141-z
Benedini, Stefano ; Ermetici, Federica ; Briganti, Silvia ; Codella, Roberto ; Terruzzi, Ileana ; Maffi, Paola ; Caldara, Rossana ; Secchi, Antonio ; Nano, Rita ; Piemonti, Lorenzo ; Alejandro, Rodolfo ; Ricordi, Camillo ; Luzi, Livio. / Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation. In: Acta Diabetologica. 2018 ; pp. 1-8.
@article{0c5c851640a2430cba1db921a3a9cfa8,
title = "Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation",
abstract = "Background: The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues. Aims: This study aimed at evaluating the effectiveness of rapamycin pre-treatment before pancreatic islet allotransplantation (ITx) in patients with type 1 diabetes mellitus (T1DM). Methods: Forty-one T1DM patients were studied. Thirteen patients with poor glycemic control underwent a short-term rapamycin treatment before ITx (Group 1), and they were compared to 28 patients undergoing ITx without rapamycin pre-treatment (Group 2). Outcomes were daily insulin requirement (DIR), fasting blood glucose, HbA1c, C-peptide and the SUITO index of beta-cell function. A subgroup of patients pre-treated with rapamycin before ITx underwent euglycemic hyperinsulinemic clamp with [6,6-2H2] glucose before and after ITx to evaluate insulin sensitivity. Results: We found a significant reduction in DIR after rapamycin pre-treatment (− 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx. DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (− 37 ± 15 vs. − 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006). Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: − 2.1 ± 1.4{\%}, p = 0.002), while fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups. Hepatic glucose production decreased after rapamycin pre-treatment (− 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (− 1.6 ± 0.6 mg/kg/min, p = 0.015), while no changes in peripheral glucose disposal were observed. Conclusions: Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity. This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance. Clinical Trial: Clinicaltrials.gov NCT01060605; NCT00014911.",
keywords = "C-peptide, Euglycemic hyperinsulinemic clamp, Insulin sensitivity, mTOR, Pancreatic islet allotransplantation",
author = "Stefano Benedini and Federica Ermetici and Silvia Briganti and Roberto Codella and Ileana Terruzzi and Paola Maffi and Rossana Caldara and Antonio Secchi and Rita Nano and Lorenzo Piemonti and Rodolfo Alejandro and Camillo Ricordi and Livio Luzi",
year = "2018",
month = "4",
day = "13",
doi = "10.1007/s00592-018-1141-z",
language = "English (US)",
pages = "1--8",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Casa Editrice II Ponte",

}

TY - JOUR

T1 - Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation

AU - Benedini, Stefano

AU - Ermetici, Federica

AU - Briganti, Silvia

AU - Codella, Roberto

AU - Terruzzi, Ileana

AU - Maffi, Paola

AU - Caldara, Rossana

AU - Secchi, Antonio

AU - Nano, Rita

AU - Piemonti, Lorenzo

AU - Alejandro, Rodolfo

AU - Ricordi, Camillo

AU - Luzi, Livio

PY - 2018/4/13

Y1 - 2018/4/13

N2 - Background: The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues. Aims: This study aimed at evaluating the effectiveness of rapamycin pre-treatment before pancreatic islet allotransplantation (ITx) in patients with type 1 diabetes mellitus (T1DM). Methods: Forty-one T1DM patients were studied. Thirteen patients with poor glycemic control underwent a short-term rapamycin treatment before ITx (Group 1), and they were compared to 28 patients undergoing ITx without rapamycin pre-treatment (Group 2). Outcomes were daily insulin requirement (DIR), fasting blood glucose, HbA1c, C-peptide and the SUITO index of beta-cell function. A subgroup of patients pre-treated with rapamycin before ITx underwent euglycemic hyperinsulinemic clamp with [6,6-2H2] glucose before and after ITx to evaluate insulin sensitivity. Results: We found a significant reduction in DIR after rapamycin pre-treatment (− 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx. DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (− 37 ± 15 vs. − 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006). Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: − 2.1 ± 1.4%, p = 0.002), while fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups. Hepatic glucose production decreased after rapamycin pre-treatment (− 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (− 1.6 ± 0.6 mg/kg/min, p = 0.015), while no changes in peripheral glucose disposal were observed. Conclusions: Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity. This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance. Clinical Trial: Clinicaltrials.gov NCT01060605; NCT00014911.

AB - Background: The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues. Aims: This study aimed at evaluating the effectiveness of rapamycin pre-treatment before pancreatic islet allotransplantation (ITx) in patients with type 1 diabetes mellitus (T1DM). Methods: Forty-one T1DM patients were studied. Thirteen patients with poor glycemic control underwent a short-term rapamycin treatment before ITx (Group 1), and they were compared to 28 patients undergoing ITx without rapamycin pre-treatment (Group 2). Outcomes were daily insulin requirement (DIR), fasting blood glucose, HbA1c, C-peptide and the SUITO index of beta-cell function. A subgroup of patients pre-treated with rapamycin before ITx underwent euglycemic hyperinsulinemic clamp with [6,6-2H2] glucose before and after ITx to evaluate insulin sensitivity. Results: We found a significant reduction in DIR after rapamycin pre-treatment (− 8 ± 6 U/day, mean ± SD, p < 0.001) and 1 year after ITx. DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (− 37 ± 15 vs. − 19 ± 13 U/day, p = 0.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta = 18.2 ± 5.9, p = 0.006). Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: − 2.1 ± 1.4%, p = 0.002), while fasting C-peptide (+0.5 ± 0.3 nmol/l, p = 0.002) and SUITO index increased (+57.4 ± 39.7, p = 0.016), without differences between the two groups. Hepatic glucose production decreased after rapamycin pre-treatment (− 1.1 ± 1.1 mg/kg/min, p = 0.04) and after ITx (− 1.6 ± 0.6 mg/kg/min, p = 0.015), while no changes in peripheral glucose disposal were observed. Conclusions: Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity. This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance. Clinical Trial: Clinicaltrials.gov NCT01060605; NCT00014911.

KW - C-peptide

KW - Euglycemic hyperinsulinemic clamp

KW - Insulin sensitivity

KW - mTOR

KW - Pancreatic islet allotransplantation

UR - http://www.scopus.com/inward/record.url?scp=85045274246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045274246&partnerID=8YFLogxK

U2 - 10.1007/s00592-018-1141-z

DO - 10.1007/s00592-018-1141-z

M3 - Article

SP - 1

EP - 8

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

ER -